Latest news with #ADC
News18
12 hours ago
- Politics
- News18
2 girl students step in as Jorhat DC, ADC for a day
Agency: PTI Jorhat, Jul 19 (PTI) Two girl students in Assam's Jorhat district on Saturday served as the district commissioner (DC) and additional deputy commissioner for the day. Both were winners of an essay competition on the topic 'One day as district commissioner', conducted as a part of 'Beti Bachao Beti Padhao' programme. The contest was open for girls of 14-25 years, with winners to get a chance to serve as DC or ADC for a day, along with other prizes. Jorhat DC Jay Shivani said the initiative was aimed at encouraging young girls to take an interest in governance. While postgraduate student Geetashree Sharma served as the district commissioner (DC), class 9 student Sanshita Baruah worked as the additional district commissioner (ADC) for the day, with both gathering an experience of a lifetime. 'This initiative was meant to encourage young girls to develop an interest in governance and aim high. Geetashree and Sanshita proved to be very capable, showing active interest in the happenings and posing questions whenever they were in doubt," Shivani said. The DC said they attended a video conference with the Chief Secretary and took an overview of the various responsibilities of the district commissioner's office. Geetashree, a student of CKB Commerce College in Jorhat, said it was a unique experience for her. 'It was a rare opportunity to observe the working of the highest office in the district from close quarters. We were explained how the policies work and decisions are implemented," she said. Student of Pragjyotika Senior Secondary School, Titabor, Sanshita was also overwhelmed with the experience. 'It was great to learn that our district is performing well in most developmental parameters," the young girl added. PTI SSG SSG RG view comments First Published: July 19, 2025, 20:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
a day ago
- Politics
- Time of India
Ruling front in Tripura to fight ADC elections independently
Agartala: The BJP-led ruling front in Tripura will fight the election to the Tripura Tribal Areas Autonomous Council (ADC), slated for early next year, separately under their respective party banners. Indigenous People's Front of Tripura ( IPFT ) and Tipra Motha are partners in the BJP-led govt. BJP on Thursday held a meeting of its tribal front leaders to discuss the preparations for the ADC polls without the participation of IPFT and Tipra Motha. IPFT on Friday held a meeting in the presence of cooperation minister of Manik Saha's cabinet Shukla Charan Noatia. He said it would contest the upcoming ADC elections with full strength, aiming for a better performance than the 2021 elections. IPFT has decided to start electioneering through the celebration of its foundation day on Aug 23, Noatia said. "We have strengthened our base and our position is better compared to previous years. Those who had left IPFT and joined other parties are now returning," Noatia said. Tipra Motha, the ruling party of ADC, is mobilising supporters on the ground. ADC's chief executive member Purna Chandra Jamatia claimed that under Tipra Motha, several social development projects have been implemented to empower the poor tribals, besides upgradation of health care facilities, skill development, and resource monetisation. However, he alleged that the state govt has not yet released half of its allocation to ADC. As a result, many of the infrastructure development projects couldn't be implemented in five years. Tipra Motha founder and member of the development council, Pradyot Kishore Debbarman, implemented several projects in ADC using his link, Jamatia said."Although we are partners in the Tripura govt, ADC didn't get adequate support and cooperation from the state; rather faced several hindrances," Jamatia said. Meanwhile, highlighting the development initiatives of the state, CM Manik Saha on Friday said his govt is working by following in the footsteps of PM Narendra Modi for the overall development and progress of the Janajati people (tribals).
Yahoo
2 days ago
- Business
- Yahoo
Astellas and KISED link to support Korean pharma startups
Astellas Pharma has entered a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED) to support Korean pharmaceutical startups' global growth. Astellas and KISED will operate the Partnership with Global Companies Program, which aims to identify these startups in Korea. Astellas chief research and development officer Tadaaki Taniguchi stated: 'We are very pleased to agree on an MoU with KISED for the operation of the Partnership with Global Companies Program. 'Astellas is committed to fostering innovation in collaboration with startups by providing the knowledge and expertise we have gained through our research and global network. We expect that the signing of this MoU will further strengthen and accelerate drug discovery research together with Korean startups, ultimately contributing to the creation of innovative medical solutions.' KISED will oversee management and provide research funding for the programme. Astellas will offer selected Korean drug-discovery startups access to facilities at SakuLab-Tsukuba within its Tsukuba research centre. These startups will benefit from consultations with Astellas experts and opportunities to expedite their drug discovery research by networking with other residents and researchers at the company. The initiative has already seen two Korean pharma and biotech firms chosen for collaboration: TCUBEiT, focusing on next-generation T-cell-based immunotherapy, and AAVATAR Therapeutics, specialising in AAV viral vector engineering technology. Both companies will commence an intensive collaborative phase by establishing operations at SakuLab-Tsukuba. In May 2025, Astellas Pharma entered an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a clinical-stage antibody-drug conjugate (ADC) that targets Claudin18.2 (CLDN18.2). Astellas agreed to pay Evopoint $130m upfront and up to $70m in near-term payments along with development, commercialisation and regulatory milestone payments totalling up to $1.34bn, and royalties on the ADC's net sales if approved. "Astellas and KISED link to support Korean pharma startups" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
2 days ago
- Business
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
BBC News
2 days ago
- Politics
- BBC News
Atiku resignation from PDP fit leave big hole for Nigeria main opposition party?
No be tori again say former vice president Atiku Abubakar don resign from Nigeria main opposition party, PDP. Sabi pipo for politics say di way Atiku Abubakar comot from di Peoples Democratic Party (PDP), fit affect di party popularity for future especially for 2027 general elections. Dis one dey come afta Atiku Abubakar, wey run for president under PDP for 2019 and 2023, announce say e don comot from di party on Wednesday. For di resignation letter wey Atiku personally sign and send give PDP Chairman for Jada 1 Ward, Adamawa State, e tok say to comot from di party pain am well-well but e no get choice. Atiku describe im exit as "heart-breaking" but necessary. E say di party don dey go one kain direction wey no follow di original reason why dem start am. Di last time wey Atiku comot from People Democratic Party (PDP) na 2014 wen e join All People Congress party (APC) help dem win 2015 election, but later e still comot from APC go back PDP for 2017. As e be now, Atiku neva join any new party. But many pipo dey reason say e fit join ADC sake of dem see am for one ADC coalition meeting wey happun for Abuja. Di party wey dem say dem wan take remove President Bola Tinubu for office for 2027 general election. Atiku exit fit affect PDP? Some political experts yarn say Atiku wey comot from PDP fit affect di party chance and reduce im popularity for future election. One political analyst from Kano, Comrade Sani Balarabe, believe say di way Atiku comot from PDP go leave big space inside di party. For interview wit BBC News Pidgin, e tok say "Atiku na big stakeholder for PDP. E get experience and supporters evriwia. If pesin like Atiku comot, e go affect di party well-well. "PDP strong, but Atiku na big name inside. If e comot, many of im people for different parts of Nigeria fit follow am go wherever e go." E also say to find anoda pesin wey fit spend money for PDP like Atiku go hard. "For politics, no be only pipo matter, money too matter. Atiku na big businessman, e get money and investment. Weda pipo like am or not, e dey sponsor many PDP activities. To find anoda pesin wey go fit do like am go tough." But Balarabe still believe say even though Atiku comot fit shake PDP, e too early to tok say PDP no go survive 2027 election. "For now, we no fit tok how PDP go be for 2027 sake of say Atiku and im pipo comot, new pipo fit still join. So e too early to conclude wetin go happun to PDP" Balarabe tok. 'Im resignation na better tin for PDP' But PDP don reply say Atiku comot no go shake dem or cause any wahala for di party. Di PDP Deputy National Publicity Secretary, Ibrahim Abdullahi, tok say na Atiku dey cause some of di problems for inside di party. "No be today Atiku dey comot. Political party no be for one person alone," Abdullahi tok. E add say "One of di complaints for Nigeria be say PDP dey look like say na Atiku get am, and e dey use am anytime e like." Abdullahi also say dem no dey worry say Atiku don comot, even though na him run for president two times and come second both times. "We no dey shake sake say di former president once tear im PDP card comot bifor, but later e still come back." E end am wit "Na pipo wey don benefit pass from di party na dem dey betray am pass."
